NovoLog (insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 85 Diseases   38 Trials   38 Trials   1659 News 


«12345678910111213...1314»
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) (clinicaltrials.gov) -  Jan 9, 2020   
    P=N/A,  N=75, Recruiting, 
    Suspended --> Recruiting | N=176 --> 75 | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2020 --> Jun 2020
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Clinical, Review, Journal:  Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. (Pubmed Central) -  Jan 8, 2020   
    Faster-acting insulin aspart is a relatively new option with the advantage of better postprandial glucose coverage. Frequent blood glucose measurements along with patient education on insulin dosing based on carbohydrate counting, premeal blood glucose, and anticipated physical activity is paramount, as is education on the management of blood glucose under different circumstances.Plain Language Summary: Plain language summary is available for this article.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
    Trial completion date, Trial primary completion date:  SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) -  Jan 8, 2020   
    P4,  N=384, Active, not recruiting, 
    Frequent blood glucose measurements along with patient education on insulin dosing based on carbohydrate counting, premeal blood glucose, and anticipated physical activity is paramount, as is education on the management of blood glucose under different circumstances.Plain Language Summary: Plain language summary is available for this article. Trial completion date: Feb 2021 --> May 2020 | Trial primary completion date: Feb 2021 --> May 2020
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    INTRA-INDIVIDUAL VARIABILITY IN SUBCUTANEOUS INSULIN ABSORPTION DURING HYBRID CLOSED-LOOP MEAL STUDY IN YOUTHS WITH TYPE 1 DIABETES: A MODELING ANALYSIS (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_374;    
    Plasma insulin aspart concentrations were measured every 10min for 4h during each meal and were used to estimate, for each subject and for each meal, a set of SC insulin absorption parameters (Figure A)...Results As shown in Figure B, mean values of model parameters have been similar between meals (p=NS); however mean intra-individual variability (CV) ranged from 34-94%, with the highest CV for the model parameter representing the direct absorption of non-monomeric insulin to plasma (ka1). Conclusions Our preliminary results suggest high intra-individual variability in SC insulin absorption during HCL treatment and underline the importance of optimizing insulin delivery algorithms to account for such variability to improve treatment outcomes.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    USE OF THE ULTRA-RAPID INSULIN FIASP IN THE ILET BIONIC PANCREAS (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_372;    
    Conclusions The iLet can provide effective glucose control when delivering Fiasp, insulin aspart, or insulin lispro. Adjustment to the PK settings of the iLet may be necessary to further improve glycemic outcomes with Fiasp.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    POSTPRANDIAL GLYCEMIC CONTROL WITH FAST-ACTING INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES USING SENSOR-AUGMENTED PUMP THERAPY. (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_348;    
    Results Postprandial hyperglycemia episodes (>140 mg/dL) were reduced by 9.1% after one month of treatment with fAsp. The continuous glucose monitoring results are shown in the following table: Conclusions After one-month follow-up with fAsp, hyperglycemia events decreased without increasing the time in hypoglycemia and without changes in the basal/bolus distribution, in patients with sensor-augmented pump therapy.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk, Afrezza (recombinant human insulin inhalation) / MannKind
    TECHNOSPHERE INSULIN PROVIDES BETTER EARLY POSTPRANDIAL GLUCOSE CONTROL THAN SUBCUTANEOUS RAPID-ACTING ANALOGUE (Berlin) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_295;    
    P3, P4
    Conclusions The TI PPGE curves confirm TI has an earlier onset and shorter duration of action, whereas the insulin aspart PPGE curves tend to drop below baseline in the late postprandial period, reflecting a longer duration of action. The timing of hypoglycemia (levels 1 and 2) follows the pattern of PPGEs.
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    How early is URLi (Ultra Rapid Lispro)? (Paris) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_257;    
    Ultra-rapid insulin lispro (URLi) was developed to more closely match physiological insulin secretion by adding two new excipients: a micro-dose of treprostinil causing local vasodilation and citrate enhancing local vascular permeability...The faster absorption of URLi was confirmed in a comparative trial versus both conventional insulin aspart (ASP) and faster insulin aspart (FIA)...Improvements in PPGs were also observed in larger clinical phase 3 trials vs. LIS. Conclusions URLi shows the fastest insulin absorption and shortest exposure duration compared to LIS, ASP and FIA leading to greater glucose lowering effects with statistically significant improvements in PPG excursions vs. LIS and ASP.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    FiAsp insulin – Evidence and experience in using it (Paris) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_256;    
    Methods Review of publiced clinical trials with FiAsp Results Efficacy of FiAsp compared to other rapid acting insulin analogs used in MDI, insulin pumps and closed loop systems will be presented together with clinical experience using FiAsp. Conclusions Based on the data presented, the need for further studies to maximize the potential of FiAsp will be discussed
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Imfinzi (durvalumab) / AstraZeneca, BMS, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. (Pubmed Central) -  Dec 13, 2019   
    Treatment with levothyroxine was commenced after excluding adrenal insufficiency (early morning cortisol: 339 nmol/L) and hypophysitis (normal pituitary on MRI)...Regular blood glucose levels should be performed on routine pathology on all patients on immune checkpoint inhibitor. Clinician awareness of immunotherapy-related diabetes needs to increase in an attempt to detect hyperglycaemia early and prevent DKA.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Clinical, Journal:  Detemir vs Glargine: Comparison of Inpatient Glycemic Control. (Pubmed Central) -  Dec 2, 2019   
    There was no significant difference between the patient groups in regard to hypoglycemic events (45% glargine vs 49% detemir; P=.59). Substituting detemir for glargine did not adversely affect inpatients' blood glucose control.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Efficacy and safety of co-formulation insulin: a real world clinical audit (Poster Area) -  Nov 20, 2019 - Abstract #IDF2019IDF_1205;    
    Mean age and mean BMI of our cohort was 59.49 years and 27.22 respectively (Table-1). Statistical significant improvement in FPG (p <0.001), PPPG (p <0.001) and HbA1c (p <0.001) were observed over an average of 24 weeks follow up, without any significant changes in weight, BMI and serum creatinine value (Table-2).
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Comparison of insulin degludec and glargine U100 in type 1 diabetes patients prone to severe nocturnal hypoglycaemia (Poster Area) -  Nov 20, 2019 - Abstract #IDF2019IDF_1110;    
    No clinically significant differences in hypoglycaemia occurrence were observed between the insulin regimens during the day. Discussion In patients with type 1 diabetes prone to nocturnal severe hypoglycamia insulin degludec reduced the risk of clinically significant nocturnal symptomatic hypoglycaemia compared with insulin glargine U100.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Tresiba e novorapid (Twitter) -  Nov 15, 2019   
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Enrollment open:  Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) -  Nov 14, 2019   
    P3,  N=220, Recruiting, 
    Discussion In patients with type 1 diabetes prone to nocturnal severe hypoglycamia insulin degludec reduced the risk of clinically significant nocturnal symptomatic hypoglycaemia compared with insulin glargine U100. Not yet recruiting --> Recruiting
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Just Novolog here. (Twitter) -  Nov 10, 2019   
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations. (Pubmed Central) -  Nov 8, 2019   
    Humulin®R and NovoRapid® were used as model formulations for MDSIs and CSII, respectively...To consider changes in conditions that may occur for insulin formulations, the relationship between the formation of precipitates and amyloids was demonstrated in vitro by using insulin formulations. From the in vitro study, m-cresol was shown to have an inhibitory effect on amyloid formation.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    New P4 trial:  Fiasp (clinicaltrials.gov) -  Nov 3, 2019   
    P4,  N=25, Not yet recruiting, 
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes. (Pubmed Central) -  Oct 29, 2019   
    Despite improving beta-cell function, insulin resistance and glucagonemia, short-term IIT does not change GLP-1 secretion and decreases the GIP response to an oral glucose challenge in early type 2 diabetes. Thus, the beneficial impact of this therapy on glucose homeostasis is not attributable to its effects on incretin secretion.
  • ||||||||||  Journal:  Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. (Pubmed Central) -  Oct 11, 2019   
    Both patients had an unequivocal diagnosis of type 2 diabetes, had poor glycaemic control with a history of metformin intolerance and presented with relatively vague symptoms post-operatively...While the mechanistic basis for EDKA remains unclear, our observation of marked ketonuria in both patients suggests that impaired ketone excretion may not be the predominant metabolic lesion in every case. Measurement of insulin, C-Peptide, blood and urine ketones as well as glucagon and renal function at the time of initial presentation with EDKA may help to establish why this problem occurs in specific patients.